In patients with pulmonary schistosomiasis, it is recommended to treat the pathogenesis with drugs as soon as the diagnosis is clear. The main reason for not using surgery as the preferred treatment here is that patients with pulmonary schistosomiasis have scattered lung lesions that are not amenable to surgical treatment, and therefore are currently treated mostly with drugs. The drug of choice is praziquantel, which is used because the side effects are mild and can be tolerated by most people. On the other hand, the treatment course of the drug is relatively short, just 3 days, and most patients are able to adhere to the drug, and the patient’s compliance is better. Moreover, after using this drug, patients can get good results through clinical observation, which show that the blood sputum disappears, the eggs in the sputum turn negative, and the lung lesions are well absorbed. If the patient has pleural effusion, after praziquantel treatment, the pleural effusion can also be significantly reduced, or even disappear. In addition to praziquantel, patients can also use albendazole for pathogenic treatment, but the duration of use is longer than praziquantel, requiring 7 days of continuous use.